Penn Medicine: 10-year remissions with CAR-T therapy in B-cell lymphoma | Source Library

Clinical resourceProfessional clinical guidance

Source type: Clinical resource
Access type: Publisher
Publisher: Penn Medicine
Date: 2026-06-24
Added: 2026-07-05

Trust profile

VV Source Trust Matrix v1.0

VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.

Professional clinical guidance

Publisher type: Professional guidance
Bias profile: Moderate

This source is strongest for safety and consumer context and weaker for mechanism and trial discovery.

VV Source Fit Score 1.0

Fit by use case

Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.

Frameworks ->

Regulatory status: 63/100; Context Source
Clinical outcomes: 78/100; Strong Support
Mechanism: 63/100; Context Source
Safety: 86/100; Strong Support
Consumer context: 82/100; Strong Support
Trial discovery: 63/100; Context Source

Best used for

Clinical context
Practice guidance

Weak for

Replacing primary evidence

Used in Viral Vitalism

Primary sourcebrief1 reference

Some Early CAR-T Lymphoma Patients Are 10 Years Out Without Relapse

Roles: Primary source

Show section-level references

Penn Medicine reports that after a median 10-year follow-up, more than one-third of large B-cell lymphoma patients and nearly half of follicular lymphoma patients in a 38-patient Phase 2 CAR-T trial were alive without relapse.